Innate Common Stock vs Other Current Liab Analysis
IPHA Stock | USD 1.55 0.14 8.28% |
Innate Pharma financial indicator trend analysis is infinitely more than just investigating Innate Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Innate Pharma is a good investment. Please check the relationship between Innate Pharma Common Stock and its Other Current Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.
Common Stock vs Other Current Liab
Common Stock vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Innate Pharma Common Stock account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.
The correlation between Innate Pharma's Common Stock and Other Current Liab is 0.36. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Innate Pharma, assuming nothing else is changed. The correlation between historical values of Innate Pharma's Common Stock and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Innate Pharma are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock i.e., Innate Pharma's Common Stock and Other Current Liab go up and down completely randomly.
Correlation Coefficient | 0.36 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Common Stock
Other Current Liab
Most indicators from Innate Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Innate Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.The current year's Selling General Administrative is expected to grow to about 14.6 M, whereas Discontinued Operations is forecasted to decline to (123.8 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 6.3M | 4.8M | 3.2M | 4.6M | Reconciled Depreciation | 4.6M | 45.4M | 5.1M | 4.8M |
Innate Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Innate Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Innate Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 401.4M | 307.4M | 267.5M | 207.9M | 184.2M | 188.0M | |
Short Long Term Debt Total | 18.7M | 19.1M | 44.3M | 42.3M | 39.9M | 41.9M | |
Other Current Liab | 43.0M | 14.3M | 14.4M | 13.0M | 15.1M | 14.8M | |
Total Current Liabilities | 121.8M | 46.7M | 79.9M | 41.3M | 39.6M | 48.6M | |
Total Stockholder Equity | 217.4M | 156.0M | 107.4M | 54.2M | 51.9M | 81.7M | |
Property Plant And Equipment Net | 11.7M | 11.7M | 10.2M | 8.5M | 6.3M | 7.9M | |
Current Deferred Revenue | 48.8M | 12.5M | 12.5M | 6.6M | 5.9M | 5.6M | |
Net Debt | (184.2M) | (117.7M) | (59.5M) | (42.0M) | (30.7M) | (32.2M) | |
Retained Earnings | (155.7M) | (220.5M) | (272.2M) | (330.3M) | (336.9M) | (320.0M) | |
Accounts Payable | 27.9M | 20.7M | 14.7M | 13.7M | 8.6M | 17.0M | |
Cash | 202.9M | 136.8M | 103.8M | 84.2M | 70.6M | 84.5M | |
Non Current Assets Total | 163.8M | 134.1M | 129.2M | 68.0M | 36.2M | 55.5M | |
Non Currrent Assets Other | 16.8M | 30.1M | 30.0M | 14.2M | 19.6M | 20.6M | |
Cash And Short Term Investments | 218.9M | 151.6M | 119.8M | 101.5M | 92.5M | 106.4M | |
Common Stock Total Equity | 2.9M | 3.2M | 3.9M | 4.0M | 4.5M | 2.5M | |
Common Stock Shares Outstanding | 66.9M | 78.9M | 79.5M | 79.6M | 80.5M | 53.1M | |
Short Term Investments | 16.0M | 14.8M | 16.1M | 17.3M | 21.9M | 16.8M | |
Liabilities And Stockholders Equity | 401.4M | 307.4M | 267.5M | 207.9M | 184.2M | 188.0M | |
Non Current Liabilities Total | 62.1M | 104.8M | 80.2M | 112.4M | 92.7M | 57.7M | |
Other Stockholder Equity | 369.6M | 372.1M | 375.2M | 379.6M | 384.3M | 216.7M | |
Total Liab | 183.9M | 151.4M | 160.1M | 153.7M | 132.3M | 106.3M | |
Property Plant And Equipment Gross | 11.7M | 11.7M | 10.2M | 8.5M | 9.8M | 8.0M | |
Total Current Assets | 237.6M | 173.3M | 138.3M | 139.8M | 148.0M | 132.5M | |
Short Term Debt | 2.1M | 2.1M | 30.7M | 2.1M | 8.9M | 9.4M | |
Common Stock | 3.9M | 4.0M | 4.0M | 4.0M | 4.0M | 2.8M | |
Net Receivables | 13.1M | 10.6M | 846K | 3.1M | 15.2M | 21.7M | |
Accumulated Other Comprehensive Income | (472K) | 355K | 456K | 819K | 495K | 519.8K | |
Inventory | 5.6M | 1.0 | (4.9M) | (2K) | (3.4M) | (3.2M) | |
Intangible Assets | 97.0M | 46.3M | 44.2M | 42.6M | 416K | 395.2K | |
Other Liab | 45.5M | 87.8M | 66.7M | 72.2M | 65.0M | 74.7M | |
Net Tangible Assets | 120.4M | 109.7M | 63.2M | 52.6M | 60.5M | 84.3M | |
Long Term Debt | 14.1M | 16.9M | 13.5M | 38.9M | 30.6M | 32.1M | |
Capital Lease Obligations | 3.1M | 3.5M | 2.8M | 2.1M | 835K | 793.3K | |
Long Term Investments | 37.0M | 38.9M | 39.9M | 35.1M | 9.8M | 9.3M | |
Short Long Term Debt | 1.5M | 2.1M | 30.7M | 1.3M | 8.5M | 5.6M | |
Property Plant Equipment | 11.7M | 11.7M | 10.2M | 8.5M | 9.8M | 10.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.41) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.